Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$325.28 USD

325.28
1,270,338

+3.37 (1.05%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $325.29 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More

by Zacks Equity Research

Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

The Zacks Analyst Blog Highlights: Disney, Amgen, Booking Holdings, General Motors, and BCE

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Disney, Amgen, Booking Holdings, General Motors, and BCE

Mark Vickery headshot

Top Analyst Reports for Disney, Amgen & Booking.com

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Amgen Inc. (AMGN), and Booking Holdings Inc. (BKNG).

Amgen's (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Amgen's (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.

Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal

by Zacks Equity Research

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.

Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb

by Zacks Equity Research

Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

by Zacks Equity Research

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q3 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.

Amgen (AMGN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 10.66% and 0.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up

by Zacks Equity Research

Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.

How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

AbbVie's (ABBV) Q3 Earnings Beat, 2021 EPS Guidance Raised

by Zacks Equity Research

AbbVie (ABBV) beats third-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares increased following the results.

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

by Sweta Killa

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $207.63, moving -0.77% from the previous trading session.

Radius (RDUS) Up On Positive Data From Breast Cancer Study

by Zacks Equity Research

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $206.78, marking a +1.8% move from the previous day.

Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

by Zacks Equity Research

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal

by Zacks Equity Research

Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal